- •We performed a study using a new coagulation biomarker in myocardial infarction.
- •The new biomarker measures how quick the clot forms, its strength and structure.
- •Therapeutic intervention caused significant changes in clot structure.
- •Changes in the new biomarker were consistent with standard SEM images of the clot.
Changes in clot microstructure are increasingly implicated in the pathology of atherosclerosis although most data are from techniques in the remote laboratory using altered blood. We validate the novel biomarker Gel Point in STEMI patients and assess therapeutic interventions. Gel Point marks the transition of blood from a visco-elastic liquid to visco-elastic solid and is rapidly measured using unadulterated blood. The Gel Point provides measurements of three parameters to reflect clot microstructure (fractal dimension (df)), real-time clot formation time (TGP) and blood clot strength (elasticity at the Gel Point (G′GP)).
We prospectively recruited 38 consecutive patients with STEMI undergoing primary percutaneous coronary intervention (pPCI). Venous blood samples were collected on admission, after pPCI and 24 h after admission for assessment of the new biomarkers, standard coagulation tests and scanning electron microscopy (SEM).
df after pPCI was lower than df on admission (mean 1.631 [SD 0.063] vs 1.751 [0.052], p < 0.000001) whereas df at 24 h was similar to that on admission. G′GP also showed similar trend to df (p < 0.001). TGP was prolonged at after-PCI measurement compared with admission (median 854 s [IQR 581–1801] vs 217 [179–305], p < 0.00001). Changes in the values of df and G′GP were consistent with changes in the SEM images of the mature clot.
We characterise Gel Point derived markers of clot microstructure in patients admitted with emergency arterial thrombosis. This point of care test can potentially be used to assess the efficacy of therapeutic interventions by measuring changes in clot microstructure.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Mechanisms of fibrin polymerization and clinical implications.Blood. 2013; 121: 1712-1719
- A new biomarker quantifies differences in clot microstructure in patients with venous thromboembolism.Br. J. Haematol. 2014; 168: 571-575
- Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives.Blood. 2009; 114: 4272-4278
- Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases.Arterioscler. Thromb. Vasc. Biol. 2011; 31: e88-e99
- Gel point and fractal microstructure of incipient clots are significant new markers of hemostasis for healthy and anticoagulated blood.Blood. 2010; 116: 3341-3344
- A new structural biomarker that quantifies and predicts changes in clot strength and quality in a model of progressive haemodilution.Thromb. Res. 2014; 134: 488-494
- Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis.Arterioscler. Thromb. Vasc. Biol. 2006; 26: 2567-2573
- Altered plasma fibrin clot properties are associated with in-stent thrombosis.Arterioscler. Thromb. Vasc. Biol. 2010; 30: 276-282
- Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease.Circulation. 2002; 106: 1938-1942
- Composition of coronary thrombus in acute myocardial infarction.J. Am. Coll. Cardiol. 2011; 57: 1359-1367
- 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J. Am. Coll. Cardiol. 2013; 61: e78-140
- Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?.Circulation. 2007; 116: 2793-2801
- Study group. The Thrombolysis in Myocardial Infarction (TIMI) Trial — phase I findings.N. Engl. J. Med. 1985; 312: 932-936
- Analysis of linear viscoelasticity of a cross-linking polymer at the gel-point.J. Rheol. 1986; 30: 367-382
- Composition dependence of the viscoelasticity of end-linked poly(dimethylsiloxane) at the gel point.Macromolecules. 1991; 24: 47-54
- Fractal dimension of a crosslinking polymer at the gel point.Macromolecules. 1986; 19: 1284-1285
- A study of microstructural templating in fibrin–thrombin gel networks by spectral and viscoelastic analysis.Soft Matter. 2013; 9: 4883-4889
- Fractal discrimination of random fractal aggregates and its application in biomarker analysis for blood coagulation.Chaos Solit. Fractals. 2012; 45: 1025-1032
- Rheometrical and molecular dynamics simulation studies of incipient clot formation in fibrin-thrombin gels: an activation limited aggregation approach.J. Nonnewt. Fluid Mech. 2011; 166: 928-932
- Deglycosylation of fibrinogen accelerates polymerization and increases lateral aggregation of fibrin fibers.J. Biol. Chem. 1988; 263: 15056-15063
- The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin.Acta Cardiol. 2012; 67: 445-448
- Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.J. Am. Coll. Cardiol. 2009; 53: 849-856
- Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy.Arter. Thromb. Vasc. Biol. 2000; 20: 1354-1361
- The effect of fibrin structure on fibrinolysis.J. Biol. Chem. 1992; 267: 24259-24263
- The mechanical properties of fibrin for basic scientists and clinicians.Biophys. Chem. 2004; 112: 267-276
- Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction.Ann. Pharmacother. 2007; 41: 737-741
- Resistance to clopidogrel: a review of the evidence.J. Am. Coll. Cardiol. 2005; 45: 1157-1164
- Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis.Arch. Intern Med. 2007; 167: 1593-1599
Published online: April 13, 2015
Accepted: April 6, 2015
Received in revised form: March 12, 2015
Received: January 16, 2015
© 2015 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.